SKYSCRAPER-03:tiragolumab联合atezolizumab对比durvalumab治疗III期NSCLC的III期研究
SKYSCRAPER-03是一项III期开放标签随机研究,评估tiragolumab联合atezolizumab对比durvalumab用于铂类同步放化疗后局部晚期不可切除III期NSCLC的巩固治疗。主要终点PD-L1阳性人群的IRF评估PFS未达到,联合组与durvalumab组的中位PFS分别为19.4个月和16.6个月(HR 0.96,95%CI 0.75-1.23,P=0.76)。联合治疗耐受性良好但未显示优于durvalumab的额外获益。
要点
- Tiragolumab联合atezolizumab未改善PD-L1阳性III期NSCLC的PFS。
- PD-L1阳性人群联合组中位PFS 19.4个月 vs durvalumab 16.6个月,HR 0.96。
- 联合治疗安全性与此前观察一致,无新发或意外发现。
核心结论
- SKYSCRAPER-03研究的主要终点未达到,tiragolumab联合atezolizumab未优于durvalumab。
研究设计与样本
- III期、开放标签、随机研究,纳入铂类同步放化疗后局部晚期不可切除III期NSCLC患者。
- 患者1:1随机接受atezolizumab(1680 mg Q4W)联合tiragolumab(840 mg Q4W)或durvalumab(10 mg/kg Q2W或1500 mg Q4W)治疗13个28天周期。
主要发现
- 中位随访33.0个月,PD-L1阳性人群联合组中位IRF评估PFS为19.4个月,durvalumab组为16.6个月(分层HR 0.96,95%CI 0.75-1.23,P=0.76)。
- PD-L1全人群中位PFS联合组为14.2个月,durvalumab组为13.8个月(分层HR 1.00,95%CI 0.84-1.19)。
- PD-L1阳性人群联合组中位OS不可估计,durvalumab组为54.8个月(分层HR 0.99,95%CI 0.73-1.34)。
- PD-L1全人群中位OS联合组为45.6个月,durvalumab组为45.8个月(分层HR 0.98,95%CI 0.80-1.20)。
- 联合治疗的安全性特征与既往观察一致,无新发或意外发现。
关键数值与推荐
- 主要终点为PD-L1阳性(肿瘤细胞≥1%)NSCLC患者的IRF评估PFS。
- 关键次要终点为OS和安全性。
临床怎么用
- 对于铂类同步放化疗后的局部晚期不可切除III期NSCLC,tiragolumab联合atezolizumab未显示优于durvalumab的获益,不支持该联合方案用于此人群的巩固治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SKYSCRAPER-03 (NCT04513925) was a phase III, open-label, randomized study that evaluated consolidation therapy with tiragolumab plus atezolizumab versus durvalumab in patients with locally advanced, unresectable, stage III, non-small-cell lung cancer (NSCLC) after platinum-based concurrent chemoradiation. PATIENTS AND METHODS: Eligible patients were randomly assigned (1 : 1) to receive either atezolizumab [1680 mg every 4 weeks (Q4W)] plus tiragolumab (840 mg Q4W) on day 1 of each cycle or durvalumab (10 mg/kg every 2 weeks or 1500 mg Q4W for those ≥30 kg body weight) on days 1 and 15 of each cycle for 13 × 28-day cycles. The primary endpoint was Independent Review Facility (IRF)-assessed progression-free survival (PFS) in patients with programmed death-ligand 1 (PD-L1)-positive (tumor cells ≥1%) NSCLC. Key secondary endpoints were overall survival (OS) and safety. RESULTS: The PD-L1 all-comers population included 413 patients randomly assigned to tiragolumab plus atezolizumab and 416 to durvalumab; the PD-L1-positive population included 209 and 210 patients in each arm, respectively. After a median follow-up of 33.0 months, median IRF-assessed PFS in PD-L1-positive patients was 19.4 months with tiragolumab plus atezolizumab compared with 16.6 months with durvalumab [stratified hazard ratio (HR) 0.96, 95% confidence interval (CI) 0.75-1.23, P = 0.76]; median PFS in PD-L1 all-comers was 14.2 compared with 13.8 months, respectively (stratified HR 1.00, 95% CI 0.84-1.19). The median OS in PD-L1-positive patients was not estimable with tiragolumab plus atezolizumab compared with 54.8 months with durvalumab (stratified HR 0.99, 95% CI 0.73-1.34); in PD-L1 all-comers, the median OS was 45.6 compared with 45.8 months, respectively (stratified HR 0.98, 95% CI 0.80-1.20). The safety profile of the combination was consistent with prior observations and there were no new or unexpected findings. CONCLUSIONS: The primary endpoint of the SKYSCRAPER-03 study was not met. Tiragolumab plus atezolizumab was tolerated but did not offer additional benefit over durvalumab.
引用
- Wakelee HA, Ahn MJ, Bradley J, et al. SKYSCRAPER-03: a phase III study of tiragolumab plus atezolizumab versus durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based concurrent chemoradiation. Ann Oncol. 2026. PMID: 42562209. doi:10.1016/j.annonc.2026.07.414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。